LYEL VS TRDA Stock Comparison

Performance

LYEL
10/100

LYEL returned -58.96% in the last 12 months. Based on SPY's performance of -13.12%, its performance is below average giving it a score of 10 of 100.

TRDA
10/100

TRDA returned -10.07% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

LYEL
54/100

LYEL receives a 53 of 100 based on 14 indicators. 7 are bullish, 6 are bearish.

TRDA
71/100

TRDA receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.

Earnings

LYEL
100/100

LYEL has missed earnings 1 times in the last 20 quarters.

TRDA
10/100

TRDA has missed earnings 4 times in the last 20 quarters.

Profit

LYEL
10/100

Out of the last 15 quarters, LYEL has had 0 profitable quarters and has increased their profits year over year on 0 of them.

TRDA
10/100

Out of the last 13 quarters, TRDA has had 1 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

LYEL
43/100

LYEL has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.

TRDA
51/100

TRDA has had a higher than average amount of volatility over the last 12 months giving it a score of 50 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Lyell Immunopharma, Inc. Common Stock Summary

Nasdaq / LYEL

Healthcare

Biotechnology

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Entrada Therapeutics, Inc. Common Stock Summary

Nasdaq / TRDA

Healthcare

Biotechnology

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Power up your portfolio